{"id":761624,"date":"2023-06-05T09:52:07","date_gmt":"2023-06-05T13:52:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/"},"modified":"2023-06-05T09:52:07","modified_gmt":"2023-06-05T13:52:07","slug":"agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/","title":{"rendered":"Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nAGEN2373 is the first CD137 agonist antibody reporting single agent responses with no major toxicity<\/p>\n<\/li>\n<li>\nResponses reported in patients with prostate cancer, ampullary carcinoma and metastatic vulvar squamous cell carcinoma<\/p>\n<\/li>\n<li>\nNo hepatic toxicities, grade \u22653 treatment-related adverse events, or dose-limiting toxicities were observed at doses up to 10 mg\/kg<\/p>\n<\/li>\n<\/ul>\n<p>LEXINGTON, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAgenus (Nasdaq: AGEN), a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, presented complete results from the monotherapy arm of the first-in-human dose escalation study of AGEN2373 (CD137 agonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting. AGEN2373 demonstrated objective responses, clinical benefit, and was well tolerated in heavily pre-treated patients with solid tumors.<\/p>\n<p>\n\u201cAGEN2373 has shown meaningful single agent activity and a favorable safety profile without evidence of liver toxicity in patients with heavily pretreated cold and immunotherapy resistant tumors,\u201d said Dr. Steven O\u2019Day, MD, Chief Medical Officer at Agenus. \u201cAGEN2373 is designed to selectively boost tumor immunity while limiting hepatotoxicity and off-target effects associated with systemic CD137 activation. These encouraging monotherapy results support further clinical trials for AGEN2373 alone and in combination with our novel immunotherapy programs.\u201d<\/p>\n<p><b>Study Design:<\/b><\/p>\n<p>\nAGEN2373 was administered intravenously at doses ranging from 0.03 mg\/kg to 10 mg\/kg in a cohort of 46 patients with advanced solid tumors and a median of 4 prior lines of therapy.<\/p>\n<p><b>Objective responses:<\/b><\/p>\n<p>\nNotable responses in the dose escalation study include:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nConfirmed partial response in a patient with vulvar squamous cell carcinoma who progressed on prior pembrolizumab<\/p>\n<\/li>\n<li>\nConfirmed partial response with complete resolution of the pancreatic lesion in a patient with ampullary carcinoma<\/p>\n<\/li>\n<li>\nConfirmed 38% reduction in target liver lesions in a castrate-resistant prostate cancer that was non-evaluable by RECIST due to palliative radiation for bone metastases<\/p>\n<\/li>\n<\/ul>\n<p><b>Tolerability:<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nNo hepatic toxicities, grade \u22653 treatment-related adverse events, or dose-limiting toxicities were observed, consistent with the molecule\u2019s design.<\/p>\n<\/li>\n<\/ul>\n<p>\nPresently, AGEN2373 is being evaluated in combination with botensilimab (multi-functional anti-CTLA-4) at a dose of 10 mg\/kg in patients with PD-(L)1 refractory melanoma.<\/p>\n<p><b>Presentation Details:<\/b><\/p>\n<p><b>Abstract Title:<\/b> A Phase 1 Study of AGEN2373, a Novel CD137 Agonist Antibody Designed to Avoid Hepatoxicity, in Patients with Advanced Solid Tumors (NCT04121676)<\/p>\n<p><b>Abstract Number:<\/b> 2524<\/p>\n<p><b>Poster Number<\/b>: 366<\/p>\n<p><b>Presenting Author:<\/b> Dr. Minal Barve, MD, Executive Director and Chief Medical Officer, Mary Crowley Research<\/p>\n<p>\nThe poster presentation can be accessed in the publications section of our website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fagenusbio.com%2Fpublications%2F&amp;esheet=53413650&amp;newsitemid=20230605005557&amp;lan=en-US&amp;anchor=https%3A%2F%2Fagenusbio.com%2Fpublications%2F&amp;index=1&amp;md5=da8d0256d64a417dd800dcc1e187e48d\">https:\/\/agenusbio.com\/publications\/<\/a>.<\/p>\n<p><b><span class=\"bwuline\">About AGEN2373<br \/>\n<br \/><\/span><\/b>AGEN2373 is a novel anti-CD137 agonist designed to stimulate T and NK cells for a durable memory response to cancer. AGEN2373\u2019s selective binding to a unique epitope is designed to prevent serious side effects associated with CD137 activation in the liver, as reported by competitor molecules.<\/p>\n<p><b><span class=\"bwuline\">About Agenus<br \/>\n<br \/><\/span><\/b>Agenus is a clinical-stage immuno-oncology company focused on developing therapies that engage the body&#8217;s immune system in fighting cancer and infections. The Company&#8217;s mission is to broaden the patient populations benefiting from cancer immunotherapy through combination approaches, leveraging a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). Agenus is headquartered in Lexington, MA. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agenusbio.com%2F&amp;esheet=53413650&amp;newsitemid=20230605005557&amp;lan=en-US&amp;anchor=www.agenusbio.com&amp;index=2&amp;md5=c7114da12caffac010ae9a6123a793a2\">www.agenusbio.com<\/a> and our Twitter handle @agenus_bio.<\/p>\n<p><b><span class=\"bwuline\">Forward-Looking Statements<br \/>\n<br \/><\/span><\/b>This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to the use of AGEN2373, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action (including validation of mechanism of action), potency, durability, and safety profile (including the absence of specific toxicities) of the Company\u2019s therapeutic candidates; and any other statements containing the words &#8220;may,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;hopes,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;forecasts,&#8221; &#8220;estimates,&#8221; &#8220;will,&#8221; \u201cestablish,\u201d \u201cpotential,\u201d \u201csuperiority,\u201d \u201cbest in class,\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230605005557r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230605005557\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230605005557\/en\/<\/a><\/span><\/p>\n<p>\nAgenus Inc.<br \/>\n<br \/>Zack Armen<br \/>\n<br \/>Investor Relations<br \/>\n<br \/>(917) 362-1370<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Zack.Armen@agenusbio.com\">Zack.Armen@agenusbio.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Infectious Diseases General Health Clinical Trials Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230605005557\/en\/381089\/3\/2_Agenus-Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO AGEN2373 is the first CD137 agonist antibody reporting single agent responses with no major toxicity Responses reported in patients with prostate cancer, ampullary carcinoma and metastatic vulvar squamous cell carcinoma No hepatic toxicities, grade \u22653 treatment-related adverse events, or dose-limiting toxicities were observed at doses up to 10 mg\/kg LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Agenus (Nasdaq: AGEN), a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, presented complete results from the monotherapy arm of the first-in-human dose escalation study of AGEN2373 (CD137 agonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting. AGEN2373 demonstrated objective responses, clinical benefit, and was well tolerated in heavily &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-761624","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO AGEN2373 is the first CD137 agonist antibody reporting single agent responses with no major toxicity Responses reported in patients with prostate cancer, ampullary carcinoma and metastatic vulvar squamous cell carcinoma No hepatic toxicities, grade \u22653 treatment-related adverse events, or dose-limiting toxicities were observed at doses up to 10 mg\/kg LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Agenus (Nasdaq: AGEN), a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, presented complete results from the monotherapy arm of the first-in-human dose escalation study of AGEN2373 (CD137 agonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting. AGEN2373 demonstrated objective responses, clinical benefit, and was well tolerated in heavily &hellip; Continue reading &quot;Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-05T13:52:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230605005557r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO\",\"datePublished\":\"2023-06-05T13:52:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\\\/\"},\"wordCount\":799,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230605005557r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\\\/\",\"name\":\"Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230605005557r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-06-05T13:52:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230605005557r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230605005557r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/","og_locale":"en_US","og_type":"article","og_title":"Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO - Market Newsdesk","og_description":"Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO AGEN2373 is the first CD137 agonist antibody reporting single agent responses with no major toxicity Responses reported in patients with prostate cancer, ampullary carcinoma and metastatic vulvar squamous cell carcinoma No hepatic toxicities, grade \u22653 treatment-related adverse events, or dose-limiting toxicities were observed at doses up to 10 mg\/kg LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Agenus (Nasdaq: AGEN), a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, presented complete results from the monotherapy arm of the first-in-human dose escalation study of AGEN2373 (CD137 agonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting. AGEN2373 demonstrated objective responses, clinical benefit, and was well tolerated in heavily &hellip; Continue reading \"Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-05T13:52:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230605005557r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO","datePublished":"2023-06-05T13:52:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/"},"wordCount":799,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230605005557r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/","name":"Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230605005557r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-06-05T13:52:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230605005557r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230605005557r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-presents-positive-efficacy-and-safety-outcomes-for-agen2373-at-asco\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/761624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=761624"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/761624\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=761624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=761624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=761624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}